Mario Anzaldua, MD
Family Medicine · Mission, TXNPI 1528003936
Payments from drug & device makers
Across 445 payments — averaging $25.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- Pfizer$1K
- Lilly USA, LLC$1K
- Novo Nordisk$989
- Johnson & Johnson$787
- Amarin Pharma, Inc.$566
- plus $4K from 30 others
What the payments were for
- Speaking & faculty fees$220%
- Food & beverage$11,27999%
- Education$520%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 57 | $3,080 |
| Pfizer | 82 | $1,114 |
| Lilly USA, LLC | 53 | $1,024 |
| Novo Nordisk | 35 | $989 |
| Johnson & Johnson | 16 | $787 |
| Amarin Pharma, Inc. | 32 | $566 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 16 | $379 |
| Amgen | 17 | $363 |
| Kowa Pharmaceuticals America, Inc. | 29 | $292 |
| Bard Peripheral Vascular, Inc. | 2 | $271 |
| AbbVie(2 entities) | 16 | $248 |
| Boehringer Ingelheim | 11 | $241 |
| E.r. Squibb & Sons, L.L.C. | 3 | $209 |
| Sanofi-aventis U.S. LLC | 11 | $177 |
| Optinose US, Inc. | 8 | $159 |
| GSK | 7 | $145 |
| Averitas Pharma Inc. | 3 | $141 |
| Astellas Pharma US Inc | 10 | $140 |
| Exact Sciences | 8 | $132 |
| Merck | 4 | $126 |
| Novartis | 2 | $116 |
| Redhill Biopharma Inc. | 1 | $110 |
| Medicure Pharma Inc. | 2 | $107 |
| Tolmar Pharmaceuticals, Inc. | 1 | $102 |
| Abbott | 4 | $83 |
| Dexcom, Inc. | 3 | $58 |
| Radius Health, Inc. | 2 | $31 |
| Corcept Therapeutics | 2 | $30 |
| Globus Medical | 1 | $28 |
| Ironwood Pharmaceuticals, Inc | 1 | $18 |
| Nevro Corp. | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| Biogen | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Mannkind Corporation | 1 | $14 |
| Paratek Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,353 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 418 | $428,060 |
| JardianceEmpagliflozin | 296 | $340,954 |
| TrulicityDulaglutide | 209 | $304,954 |
| MounjaroTirzepatide | 188 | $201,415 |
| LinzessLinaclotide | 197 | $140,222 |
| MyrbetriqMirabegron | 151 | $134,940 |
| EliquisApixaban | 146 | $131,995 |
| VascepaIcosapent Ethyl | 217 | $129,057 |
| FarxigaDapagliflozin Propanediol | 105 | $124,634 |
| Bydureon BciseExenatide Microspheres | 67 | $92,850 |
| XareltoRivaroxaban | 75 | $84,311 |
| TradjentaLinagliptin | 56 | $61,619 |
| JanuviaSitagliptin Phosphate | 46 | $57,752 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 87 | $54,036 |
| Tresiba Flextouch U-100Insulin Degludec | 65 | $53,588 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $1,024 | $506,369397 claims |
| Novo NordiskOzempic, Rybelsus | $989 | $478,024446 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy, Synjardy Xr | $241 | $442,526407 claims |
| AbbVieLinzess | $248 | $140,222197 claims |
| Astellas Pharma US IncMyrbetriq | $140 | $134,940151 claims |
| PfizerEliquis | $1,114 | $131,995146 claims |
| AstraZenecaFarxiga | $3,080 | $124,634105 claims |
| MerckJanuvia, Janumet, Lagevrio (Eua) | $126 | $101,97397 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $145 | $91,158170 claims |
| Johnson & JohnsonXarelto | $787 | $84,31175 claims |
| AmgenProlia | $363 | $53,46532 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $292 | $26,93843 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Mission
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
- Bonnie ColvilleHouston$19.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.